1-20 of 199
Philippe Moreau, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Peripheral Neuropathy in the Cassiopeia Study

Cathelijne Fokkema, MD, Bronno Van Der Holt, PhD, Mark van Duin, PhD, Ruth Wester, MD, Tom Cupedo, PhD, Philippe Moreau, MD, Jessica Vermeulen, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48.
https://doi.org/10.1182/blood-2020-137400
Published: 2020
Journal Articles

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Maria Mateos, MD PhD, Maria Gavriatopoulou, Thierry Facon, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Roman Hajek, MD, Meletios A Dimopoulos, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-138391
Published: 2020
Journal Articles

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study

Ola Landgren, MD PhD, Katja Weisel, MD, Laura Rosinol Dachs, Philippe Moreau, MD, Mehmet Turgut, MD, Roman Hajek, MD PhD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Jin Seok Kim, MD PhD, Jianqi Zhang, Ning Go, PhD, Christopher L. Morris, PhDMD, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
https://doi.org/10.1182/blood-2020-141291
Published: 2020
Journal Articles

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Philippe Moreau, MD, Ajai Chari, Mathias Haenel, MD, Albert Oriol, Paula Rodriguez-Otero, MD PhD, Helen McCarthy, PhD FRCPath, Kenshi Suzuki, MD PhD, Vania T. M. Hungria, MD PhD, Anna Sureda Balari, MD PhD, Lauriane Clement-Filliatre, MD, Cyrille Hulin, MD, Hila Magen, MD, Shinsuke Iida, MD PhD, Vladimir Maisnar, MD, Lionel Karlin, MD, Luděk Pour, MD, Cyrille Touzeau, Shiyi Yang, Michele Kosh, Maria Delioukina, Christoph Heuck, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–30.
https://doi.org/10.1182/blood-2020-134935
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137154
Published: 2020
Journal Articles

Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

Thomas Chalopin, Nicolas Vallet, MD, Marlene Ochmann, MD, Mourad Tiab, Pascal Godmer, Carole Barin, Olivier Theisen, MD, Olivier Herault, MD PhD, Emmanuel Gyan, MD PhD, Lotfi Benboubker, MD, Philippe Moreau, MD, Herve Avet-Loiseau, Cyrille Touzeau
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-139436
Published: 2020
Journal Articles

Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study

Enrique M. Ocio, MDPhD, Aurore Perrot, Pierre Bories, MD, Jesus F. San-Miguel, MD PhD, Igor W Blau, MD PhD, Lionel Karlin, MD, Joaquin Martinez-Lopez, MD PhD, Wolfram Pönisch, MD, Sara Bringhen, MD, Fabio Ciceri, MD, María-Victoria Mateos, MD PhD, Paula Rodriguez-Otero, Nadia Le Roux, Yvonne Dong, Thomas Fitzmaurice, PhD, Corina Oprea, MD, Philippe Moreau, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-136569
Published: 2020
Journal Articles

A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Akshanth R. Polepally, PhD, Monica Motwani, PhD, Yunming Mu, PhD, Zeena Salman, MPH, Sudhir Penugonda, MD MPH, Philippe Moreau, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-137037
Published: 2020
Journal Articles

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Larysa Sanchez, MD, Xavier Leleu, MD, Jennifer Beaumont, Hailin Yu, Stacie Hudgens, MA, Holger W Auner, MD PhD, Hang Quach, MD, Sosana Delimpasi, MD, Ivan Spicka, MD PhD, Luděk Pour, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD PhD, Reuben Benjamin, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Nizar J. Bahlis, MD, Thierry Facon, MD, Yi Chai, Xiwen Ma, Shijie Tang, Hoyee Leong, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-141319
Published: 2020
Journal Articles

Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

Jacob P. Laubach, MD, Fredrik Schjesvold, MDPhD, Mário Mariz, Meletios A Dimopoulos, Ewa Lech-Marańda, MD PhD, Ivan Spicka, MD PhD, Vania T. M. Hungria, MD PhD, Tatiana Shelekhova, Andre Abdo, MD, Lutz Jacobasch, Chantana Polprasert, MD, Roman Hajek, MD PhD, Arpad Illes, MD, Tomasz Wróbel, MD PhD, Anna Sureda Balari, MD PhD, Meral Beksac, MD, Iara Goncalves, Joan Bladé Creixenti, S. Vincent Rajkumar, MD, Ajai Chari, MD, Sagar Lonial, MD FACP, Andrew Spencer, Pierre Maison-Blanche, Philippe Moreau, MD, Paul G. Richardson, MD, Jesus F. San-Miguel, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–6.
https://doi.org/10.1182/blood-2020-140697
Published: 2020
Journal Articles

Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Baptiste Le Calvez, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Amandine Le Bourgeois, MD, Marie Audrain, MD PhD, Marion Eveillard, Thomas Dejoie, Béatrice Mahé, MD, Viviane Dubruille, Nicolas Blin, MD, Cyrille Touzeau, Thomas Gastinne, MD, Anne Lok, Benoit Tessoulin, MD PhD, Sophie Vantyghem, Steven Le Gouill, MD PhD, Philippe Moreau, MD, Marie C Bene, PharmSci, PhD, Patrice Chevalier, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136743
Published: 2020
Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Marcelo Capra, MD PhD, Thomas Martin, III, MD, Philippe Moreau, MD, Ross Baker, MBBS, FRACP, FRCPA, BSc, Ludek Pour, MD, Chang-Ki Min, MD PhD, Xavier Leleu, MD, Mohamad Mohty, MD PhD, Marta Reinoso Segura, Mehmet Turgut, MD, Richard Leblanc, MD FRCPC, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-136415
Published: 2020
Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Noopur S. Raje, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Sagar Lonial, MD FACP, Nikhil C. Munshi, MD, Philippe Moreau, MD, Hartmut Goldschmidt, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Liping Huang, PhD, Amit Agarwal, MD PhD, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Jesus F. San-Miguel, MD PhD, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-134319
Published: 2020
Journal Articles

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E. O'Dwyer, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shaji K. Kumar, MD, Rakesh Popat, Philippe Moreau, MD, Monique Dail, PhD, Muhammad Jalaluddin, PhD, Xiaoqing Yang, PhD, Xin Lu, Zheng Zha, Fengjiao Dunbar, PhD, Deeksha Vishwamitra, PhD, Christine Mantis, PhD, Amal Melhem-Bertrandt, MD, Jeremy A. Ross, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-134710
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Holger W Auner, MD PhD, Maria Gavriatopoulou, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Meletios A Dimopoulos, Irina Kryachok, Professor, Halyna Pylypenko, MD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria Mateos, MD PhD, Michele Cavo, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137303
Published: 2020
Journal Articles

Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study

Jean-Baptiste Alberge, Bastien Jamet, Clement Bailly, Cyrille Touzeau, Jonathan Cruard, Thomas Carlier, Caroline Bodet-Milin, Michel Cherel, Philippe Moreau, MD, Stephane Minvielle, Francoise Kraeber-Bodere
Journal: Blood
Blood (2020) 136 (Supplement 1): 26.
https://doi.org/10.1182/blood-2020-140235
Published: 2020
Journal Articles

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Maria Mateos, MD PhD, Sundar Jagannath, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, MD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–52.
https://doi.org/10.1182/blood-2020-137574
Published: 2020
Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Aurore Perrot, Valerie Lauwers-Cances, Titouan Cazaubiel, Thierry Facon, MD, Denis Caillot, Lauriane Clement-Filliatre, Margaret Macro, Olivier Decaux, Karim Belhadj, Mohamad Mohty, Lionel Karlin, MD, Jean Claude Eisenmann, Mourad Tiab, Frederique Orsini, Cyrille Touzeau, Xavier Leleu, MD, Herve Avet-Loiseau, Nikhil C. Munshi, MD, Kenneth Anderson, MD, Paul G. Richardson, MD, Philippe Moreau, MD, Michel Attal
Journal: Blood
Blood (2020) 136 (Supplement 1): 39.
https://doi.org/10.1182/blood-2020-134538
Published: 2020
Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD, Mario Boccadoro, Sosana Delimpasi, MD, Meral Beksac, MD, Eirini Katodritou, MD, Philippe Moreau, MD, Luca Baldini, MD PhD, Argiris Symeonidis, MD PhD, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, MD PhD, Hermann Einsele, MD, Ioannis Orfanidis, Tahamtan Ahmadi, MD PhD, Jon Ukropec, PhD, Tobias Kampfenkel, MD, Jordan Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, MD PhD, Robin Carson, MD BA, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135874
Published: 2020
Journal Articles

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, MD, Joseph Mikhael, MD FRCPC, MD, Roman Hajek, MD, Kihyun Kim, MD PhD, Kenshi Suzuki, MD PhD, Cyrille Hulin, MD, Mamta Garg, MD FRCP, FRCPath, Hang Quach, MDFRACP,FRCPA,MBBS, Hanlon Sia, Anup George, Tatiana Konstantinova, MD PhD, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, MD PhD, Philippe Moreau, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-137681
Published: 2020